Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy agree Actos generic deal

Ranbaxy Laboratories has reached an agreement with Takeda to launch a generic version of its blockbuster diabetes drug, Actos, in the US

Ranbaxy Laboratories has reached an agreement with Takeda Pharmaceuticals to launch a generic version of its blockbuster diabetes drug treatment, Actos (pioglitazone hydrochloride), in the US.

The deal will see the two companies resolve patent litigation that has been outstanding since makers of Actos, Takeda sued Ranbaxy, along with Watson Pharmaceuticals and Mylan Laboratories, in 2003 over potential generic versions.

Full terms of the settlement have yet to be disclosed, though Takeda will grant Ranbaxy, India's largest pharmaceutical company, a non-exclusive royalty free license to its US patents covering Actos. Ranbaxy will be allowed to launch its generic version in the US on August 17, 2012, or earlier under certain circumstances.

Takeda had previously announced a similar agreement with Watson Pharmaceuticals regarding their own generic version of Actos.

Jim Meehan, vice president of sales and distribution for Ranbaxy Pharmaceuticals Inc (RPI), part of the Ranbaxy family, said: "This agreement will allow RPI to bring to patients with diabetes a generic alternative in this important therapeutic area."

Actos is one of Takeda's biggest selling drugs, achieving around $3.4bn in brand sales for 2009.

16th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics